Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Where multidisciplinarity meets global collaboration – join us in Berlin, or online, for an event that promises to drive progress in oncology
The nomination process for the 2025 ESMO Society Awards is now open. ESMO Members may nominate candidates for the Awards before 12 March 2025
Staying updated with the latest advancements in cancer care has never been easier. Mark your calendar for the upcoming Advanced Urothelial Cancer Webinar (19 Feb)
The latest in early phase trials, including bispecific antibodies for IO, radiotheranostics, MAPkinase and associated targets (KRAS G12C, MAP2K4, combos) and more, will be presented in this multi-stakeholder forum
Application deadline: 15 April 2025
Michel Ducreux, Teresa Macarulla, and Eric Van Cutsem, ESMO GI 2025 Scientific Co-Chairs, encourage you to share your research!
Join experts to explore cutting-edge insights into sarcoma and rare cancers: multidisciplinary care, molecular diagnostics, precision therapies, and research advancements to improve patient outcomes
Be the force driving innovation in cancer drug development and make the latest advances in early clinical trials accessible to everyone in Asia
Online application is now open until 18 February 2025
Is your ESMO Library up to date? We published three new titles last year: Breast Cancer, Gynaecological Tumours and Lymphomas - all written with young oncologists in mind
Online application is open until 26 March 2025
A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Robust measures aimed at discouraging people from using tobacco products are a key requisite for driving back Europe’s cancer burden
It is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy
Evidence for efficacy is based on the results from the CodeBreaK 300 study
However, secondary endpoints of the TROPION-Breast01 continue to support a potential benefit of the antibody-drug conjugate in previously treated patients
ESMO has shared key concerns on cancer prevention and control with H.E Ms. Inga Rhonda King and H.E. Ambassador Olivier Maes
In patients with resectable, locally advanced oesophageal adenocarcinoma or OGJ, pre- and post-operative ChT is associated with improved survival compared with neoadjuvant CRT.
Findings from the CheckMate 7FL and KEYNOTE-756 studies
ESMO official statements to the 156th World Health Organisation Executive Board meeting in Geneva, 3.-11. February 2025, highlighted the society’s efforts to shape a range of policies related to Rare Cancers, the Oncology Workforce, Cancer Care During Health Emergencies, and Air Pollution
This year marks the 10th anniversary of the ESMO Women for Oncology (W4O) Committee, a decade-long commitment to advancing gender equity in oncology
It is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy
Evidence for efficacy is based on the results from the CodeBreaK 300 study
Findings from the CheckMate 7FL and KEYNOTE-756 studies
Findings from a final analysis of the JAVELIN Renal 101 study
Findings from the ESOPEC study
Evidence for efficacy is based on the results from the CHECKMATE-67T study
Evidence for efficacy is based on the results from the eXALT3 study
Findings from the CheckMate 8HW study
Findings from a randomised, controlled study
The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology
The ESMO Asia Congress 2024 is the annual event dedicated to multidisciplinary oncology in the Asian region
The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics
Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024
Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers
The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand
The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.
The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a paper published today in ESMO Open
According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers
This year marks the 10th anniversary of the ESMO Women for Oncology (W4O) Committee, a decade-long commitment to advancing gender equity in oncology
ESMO reaffirms its commitment to working with EU stakeholders to maximize the potential of the Beating Cancer Plan
Bringing together cancer patient advocates from around the world will create a bridge between diverse experiences and perspectives and help secure the optimisation of patient care worldwide
The nomination process for the 2025 ESMO Society Awards is now open
The European Society for Medical Oncology (ESMO) has announced today that the recipient of the 2025 TAT Honorary Award is Philippe Bedard
ESMO welcomes the outcome of the hearings for Olivér Várhelyi, Commissioner-designate for Health and Animal Welfare, where several topics relevant for the oncology community were addressed in a positive or at least promising way
The ESMO Award for Immuno-Oncology 2024 is presented to Ton N. Schumacher in recognition of his exceptional contributions to cancer immunology and to our understanding of the mechanism of how immunotherapy works
Bringing another annual reunion of the global oncology community to a resounding close, the 34,000 attendees of the ESMO Congress 2024 had the opportunity to gather around to listen to the most important results presented in different tumour types and research areas
ESMO is pleased to announce the 2024 ESMO Fellowship awardees
However, secondary endpoints of the TROPION-Breast01 continue to support a potential benefit of the antibody-drug conjugate in previously treated patients
Findings are from an exploratory subgroup analysis of the KEYNOTE-826
The updated Antineoplastic Medicine Survey (ANMS) dataset shows that essential therapies remain out of reach for patients in most low and lower middle-income countries despite international efforts
Updated results from the KEYNOTE-756 trial show benefits of the chemoimmunotherapy across subgroups of patients with ER+/HER2− breast cancer
The reduced efficacy compared to the first-line standard of care led to the termination of the SKYSCRAPER-06 study
Early-phase data suggest that intratumour injections of ORCA-010 may convert cold tumours into immunogenic ones
Effectiveness, applicability and accessibility measure the value of novel technologies and therapies in oncology
Recent findings consolidate the role of liquid biopsy in the field, but prospective research is needed
Despite being active in this disease setting, the antibody-drug conjugate was associated to high rates of neutropenic complications
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
France
United Kingdom
Switzerland
France
Switzerland
Peru
Germany
Netherlands
Austria
Spain
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
ESMO Examination 2025 will be held on Saturday 18 October during the ESMO Congress 2025.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
